Mon, Dec 22, 2014, 10:06 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • howcomethisdoesnotwork howcomethisdoesnotwork Aug 14, 2013 11:03 AM Flag

    Easily worth $25 a share with FDA approval, long term +$100 a share

    Given the market cap, and the potential growth in the market over the next decade, this is easily worth over $100 a share, given the market and current data this is easily worth $25 a share today, and once the analysts and medical professionals peer review the data in the coming days/weeks, more information will be presented and published, and more partners would be announced before any FDA approval dates.

    The share price is only going to appreciate over time from here steadily like it did since last years $2 lows.

    Unless there is substantial scientific evidence of failure.

    I wonder if they can seek FAST track status or something along those lines given the meeting already in the past, and somehow obtain approval by Q1 2014.

    Please comment on where you value the company given the global market value of these treatments, and note, that there are other products in the pipeline that could progress in the coming year, building value.

    Today the day traders and gamblers will be pulling out on this news, but they don't realize the bigger picture, i bet in hours, or a few days the share price goes into the teens.

5.38+0.0200(+0.37%)Dec 22 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Gilead Sciences Inc.
NASDAQMon, Dec 22, 2014 4:00 PM EST
Ocwen Financial Corp.
NYSEMon, Dec 22, 2014 4:00 PM EST